PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|April 20, 2018
Federal Judge Enters Consent Decree With Drug Compounder
Author(s)Pharmaceutical Technology Editors
A federal judge from the Eastern District of Arkansas entered into a consent decree with Cantrell Drug Company.
Advertisement
On April 19, 2018, a US district judge for the Eastern District of Arkansas entered into a consent decree of permanent injunction between the United States and Cantrell Drug Company of Little Rock, Arkansas and James L. McCarley, Jr., the company’s chief executive officer and co-owner. Cantrell and McCarley are prohibited from manufacturing, processing, packing, holding, or distributing drugs until they comply with the Federal Food, Drug, and Cosmetic Act (FD&C Act) and FDA regulations.
According to FDA, Cantrell, a drug compounder registered as an outsourcing facility under the FD&C Act, manufactured and distributed adulterated injectable opioids and antibiotics that were purportedly sterile. FDA stated in a
Under the consent decree, Cantrell is required to cease operations, complete corrective actions, and hire an independent current good manufacturing practices consultant. The company must receive FDA authorization before it can resume operations.
Source:
Advertisement
Related to this article
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
AI can turn medical device risk management into a continuous signal.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Advertisement
Advertisement